Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])
Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])
To understand the safety and efficacy of Revlimid® 2.5mg and 5 mg Capsules (hereinafter
 referred to as Revlimid) in all patients who are treated with it under the actual condition
 of use pursuant to the conditions of approval.

 1. Planned registration period This period started on the date of initial marketing of
 Revlimid and will end at the time when the planned number of patients to be enrolled is
 reached.

 2. Planned surveillance period This period started on the date of initial marketing of
 Revlimid and will end on the day when the approval condition related to all-case
 surveillance is terminated.
Inclusion Criteria:

 -  Newly-diagnosed multiple myeloma who are treated with Revlimid Capsules

 Exclusion Criteria:

 -  N/A